From 1 January 2021, the Medicines and Healthcare products Regulatory Agency (MHRA) will be making independent regulatory decisions. Guidelines are in place, and the ABPI has called for support to help sponsors navigate the changes. Read on to learn more about this new era of independence for the agency.
In our latest article, we explore how PharmaMedic Consultancy (PMC®) supports Glenmark Pharmaceuticals with their day to day promotional activities. Read on to learn how our medical affairs consultant seamlessly fits into our client's team and ensures commercial compliance.
Collaboration is essential to drive innovation in pharma and bring new medicines to patients. In this article, we discuss how close cooperation between regulatory and medical affairs helps to streamline regulatory interactions.
Now more than ever, we need to apply old-fashioned common sense to help drive advances in healthcare. In this article we discuss how reconfiguring and repurposing of medicines have come to the fore during the COVID-19 pandemic.
Like all sectors, the pharmaceutical industry is facing an unparalleled period of uncertainty. As experienced pharmaceutical consultants, we are well equipped to adapt, thrive and add value in this changing environment. In this article, we explore some of the skills and qualities that we need to embrace now more than ever.
PharmaMedic's VirtualPharma™ Solution is backed by decades of medical affairs experience and built on four key pillars. Read more to learn how we help pharma and biotech companies of all sizes with flexible solutions.
Navigating the information overload of COVID-19 is a challenge. In this short update, PharmaMedic rounds up some top resources for individuals, pharma and biotech researchers.
Outsourcing medical affairs could be your next best strategic move. Learn how in PharmaMedic’s latest blog.
Trump effect on Intellectual Property, Pricing, R&D in global trade deals.
